This retrospective study examined the differences in the prognostic impact of the haematopoietic cell transplantation-specific comorbidity index (HCT-CI) on transplant outcomes by disease status and time from transplant in allogeneic haematopoietic stem cell transplantation (HSCT) recipients at a Japanese transplant centre. Of 187 patients, nonrelapse mortality (NRM) at 3 years was 9.6, 21.2 and 27.8% in the low-risk (score 0), intermediate-risk (score 1-2) and high-risk (score X3) HCT-CI groups, respectively (P ¼ 0.03). The corresponding overall survival (OS) at 3 years was 70.1, 60.5 and 38.9%, respectively (Po0.01). In multivariate analyses, high-risk HCT-CI significantly predicted higher NRM (relative risk, (RR) 2.44 (95% confidence interval, (CI) 1.02-5.85); P ¼ 0.04) and worse OS (RR 2.02 (95% CI 1.15-3.54); P ¼ 0.01). In the subgroup analysis according to disease status, the HCT-CI was associated with OS (Po0.01) and NRM (P ¼ 0.07) in patients with low-risk diseases, but not in those with high-risk diseases. Within patients who survived without relapse 41 year after HSCT, the HCT-CI did not predict OS (P ¼ 0.59) or NRM (P ¼ 0.31). These findings can be useful to determine the role of pretransplant comorbidity in allogeneic HSCT.
Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many patients diagnosed with haematologic malignancies. The advent of nonmyeloablative conditioning regimens allowed us to extend the indications of allogeneic HSCT to patients with older age or coexisting comorbidities. However, this treatment procedure can still be associated with significant treatment-related mortality and morbidity.
Recently, the haematopoietic cell transplantation-specific comorbidity index (HCT-CI) has been proposed to effectively capture pretransplant comorbidities and predict the probability of nonrelapse mortality (NRM) and overall survival (OS) in allogeneic HSCT recipients. 1 Earlier studies have examined and validated the HCT-CI as a good prognostic indicator in patients with various haematologic malignancies. [2] [3] [4] [5] [6] However, some points still need to be clarified. First, considering regional and racial differences in the prevalence and severity of comorbidities, this tool needs to be validated outside western countries as well. However, to our knowledge, few studies evaluating this score have been performed outside western countries. Although an earlier study in Japan investigated the impact of pretransplant comorbidity on transplant outcomes, it did not cover comprehensive items included in the HCT-CI scoring system. 7 Second, an observational study in a hospital-based cancer registry suggested that the prognostic impact of comorbidities would be greater for patients with cancers associated with a long natural history and less for those with aggressive cancers. 8 Although the prognostic impact of pretransplant comorbidity may differ according to disease status at transplantation, this possible difference has not been investigated in HSCT recipients. Third, allogeneic HSCT recipients are at risk for not only early, but also late transplant-related complications, including chronic graft-vs-host disease (GVHD), late toxicities associated with conditioning regimens, as well as bacterial, fungal and viral infections. 9, 10 Although earlier studies showed that the HCT-CI is associated with transplant outcomes, 2-6 they did not differentiate the impact of the HCT-CI on early and late NRM. Thus, whether the HCT-CI can predict late NRM remains unknown.
The aims of this study were (i) to clarify the prevalence of pretransplant comorbidities and evaluate whether the HCT-CI predicts NRM and OS in allogeneic HSCT recipients with adequate pretransplant workup needed to obtain this score at a Japanese transplant centre; (ii) to assess the difference in the prognostic impact of comorbidity on transplant outcomes between patients with low-and high-risk diseases and (iii) to investigate whether the HCT-CI predicts NRM in patients who survived without relapse 41 year after HSCT to examine the influence of the HCT-CI on late NRM.
Materials and methods

Patients
This analysis included consecutive adult patients (X16 years old) with haematologic malignancies who underwent T-cell replete allogeneic HSCT at the University of Tokyo Hospital, Japan, between June 1996 and October 2006. Seven patients who received both bone marrow and peripheral blood stem cell transplantation and four patients who received cord blood transplantation during this time period were excluded from this analysis. Of the 233 eligible patients, 46 did not have adequate data regarding pretransplant comorbidities available to obtain the HCT-CI score. Therefore, the final study cohort consisted of 187 HSCT recipients. There was no significant difference in the probability of NRM and OS between the 46 excluded patients and those included in this analysis.
This study was performed in accordance with the Helsinki Declaration and approved by the Ethics Committee of the University of Tokyo Hospital.
Myeloablative conditioning regimens included either total body irradiation (TBI)-based regimens or non-TBIbased regimens. TBI-based regimens mainly consisted of cyclophosphamide (60 mg/kg/day for 2 days (total dose 120 mg/kg)) plus fractionated TBI (12 Gy), whereas non-TBI-based regimens busulfan (1 mg/kg every 6 h for 4 days (total dose 16 mg/kg)) plus cyclophosphamide (60 mg/kg/ day for 2 days (total dose 120 mg/kg)). Patients were offered nonmyeloablative conditioning regimens because they were ineligible for conventional HSCT because of old age (455 years), preexisting significant medical problem and history of high-dose HSCT. Nonmyeloablative conditioning regimens consisted of fludarabine-based regimens with or without low-dose TBI (4 Gy). Prophylaxis for GVHD was performed with calcineurin inhibitors (cyclosporine or tacrolimus) with or without short-term methotrexate. Human leucocyte antigen (HLA) matching for donor selection was based on serologic typing for HLA-A and -B antigens, and molecular typing for HLA-DRB1 allele. Prophylaxis against bacterial infection was performed with tosufloxacin, fungal infection with fluconazole, herpes simplex virus infection with acyclovir and Pneumocystis jiroveci infection with sulfamethoxazole/ trimethoprim.
Disease morphology was determined according to the French-American-British classification. Low-risk diseases were defined as acute leukaemia in first or second complete remission, chronic myeloid leukaemia in first or second chronic phase, chemosensitive lymphoma and myelodysplastic syndrome in refractory anaemia or refractory anaemia with ringed sideroblasts. All other conditions were classified as high-risk diseases.
Data collection
Pretransplantation comorbidities were assessed retrospectively by comprehensive review of medical records and computer database system according to the HCT-CI classification. 1 The comorbidities captured by this tool include arrhythmia, cardiac disease, inflammatory bowel disease, diabetes, cerebrovascular disease, psychiatric disturbance, altered hepatic function, obesity, infection, rheumatologic disorder, peptic ulcer disease, renal insufficiency, pulmonary abnormality, prior solid tumour and heart valve disease. Laboratory values were collected before the beginning of conditioning regimens. Pulmonary function tests and evaluation of left ventricular ejection fraction by ultrasound cardiography were performed within 3 months before transplantation as part of routine pretransplant workup. Each patient was assigned a comorbidity score and was stratified into low-risk (score 0), intermediate-risk (score 1-2) and high-risk (score X3) groups based on their total score.
Information concerning performance status was collected by comprehensive review of medical records and assessed as per the Karnofsky scale. The Karnofsky performance status scores were categorized as low (p80%) or high (480%) in accordance with an earlier report. 5 
Statistical methods
The duration of follow-up was the time from transplant to the last assessment for survivors. Variables related to the patients, the underlying diseases and the transplantation procedures were compared between the groups with the Fisher's exact test for categorical variables and the Mann-Whitney U-test for continuous variables. Probabilities of OS were calculated with the Kaplan-Meier method; the log-rank test was used for univariate comparisons.
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For analyses of OS, death from any cause was considered as an event and data on patients who were alive at the last follow-up were censored. Probabilities of NRM, relapse rate and chronic GVHD were calculated with the use of the cumulative-incidence-function method. 12 For NRM, relapse was the competing event; for relapse, NRM was the competing event; for GVHD, death without GVHD was the competing event. Data on patients who were alive without an event were censored at the last follow-up.
The association of the HCT-CI and transplant outcomes was evaluated in multivariate analyses, with the use of Cox proportional-hazards regression for OS 11 and Fine and Gray's proportional-hazards model for subdistribution of a competing risk for NRM. 13 The variables considered in multivariate analyses were age, disease status at transplantation, graft source, donor type, conditioning regimen, history of prior transplantation, year of transplant, HCT-CI and Karnofsky performance status.
The relative-risk estimates with their 95% confidence intervals and respective P-values were reported from these analyses. All P-values are two sided, with a type I error rate fixed at 0.05. Statistical analyses were performed with R 2.8.1 software (The R Foundation for Statistical Computing, 2009).
Results
Patients
We reviewed the records of 187 adult patients who underwent allogeneic HSCT for haematologic malignancies at our institution. Their clinical characteristics are shown in Table 1 . In all, 108 (58%) of patients had low-risk diseases and 79 (42%) patients had high-risk diseases. As compared with patients with low-risk diseases, patients with high-risk diseases were more likely to be male, have myelodysplastic syndrome, have histories of prior transplantations, have high-risk HCT-CI and have low Karnofsky performance status. Patients with high-risk diseases were less likely to have acute lymphoblastic leukaemia and chronic myeloid leukaemia.
HCT-CI
The distribution of individual comorbidities that define the HCT-CI is shown in Figure 1 . Hepatic dysfunction was the most common comorbidity in our cohort (42%), including 32% with mild and 10% with moderate/severe hepatic comorbidity. Other common comorbidities were pulmonary (35%) and infection (6%). No patient had obesity, rheumatologic disease, moderate/severe renal insufficiency and history of prior solid tumour. As compared with patients with low-risk diseases, patients with high-risk diseases were more likely to have infection (P ¼ 0.03), moderate/severe hepatic (P ¼ 0.08) and severe pulmonary comorbidity (P ¼ 0.08).
OS and NRM
Median follow-up period for survivors after HSCT was 69.4 months (range, 8.8-162.8 months). Overall, OS, NRM and relapse rate at 3 years were 57.7, 19.0 and 27.4%, respectively. Three-year OS was 70.1, 60.5 and 38.9% in the low-, intermediate-and high-risk HCT-CI groups, respectively (Po0.01) (Figure 2a) . Three-year cumulative NRM was 9.6, 21.2 and 27.8% in the low-, intermediate-and high-risk HCT-CI groups, respectively (P ¼ 0.03) (Figure 2b ). Three-year cumulative relapse rate was 22.8, 25.8 and 35.2% in the low-, intermediate-and high-risk HCT-CI groups, respectively (P ¼ 0.25). In univariate analyses, the patients with high-risk HCT-CI scores had worse OS (Po0.01) and higher NRM (Po0.01) than those with low-risk HCT-CI scores, but those with intermediaterisk HCT-CI scores had similar OS (P ¼ 0.35) and NRM (P ¼ 0.18) compared with those with low-risk HCT-CI scores. Multivariate analyses of risk factors among all patients showed that high-risk HCT-CI and high-risk disease significantly predicted worse OS. High-risk HCT-CI was the only significant risk factor associated with increased NRM (Table 2) .
HCT-CI and disease status At 3 years, patients with low-risk diseases had significantly better OS (72.6% vs 37.5%; Po0.01) and lower relapse rate (14.9% vs 44.3%; Po0.01), but similar NRM (16.0% vs 23.2%; P ¼ 0.14) compared with those with high-risk diseases. After relapse, patients with low-risk diseases were more likely to undergo second allogeneic transplantation than those with high-risk diseases (4 out of 16 with low-risk diseases and 1 out of 36 with high-risk disease; P ¼ 0.03). For patients with low-risk diseases, 3-year OS was 86.9, 67.4 and 56.5% in the low-, intermediate-and high-risk HCT-CI groups, respectively (Po0.01) (Figure 3a) . Threeyear cumulative NRM was 4.9, 20.8 and 26.1% in the low-, intermediate-and high-risk HCT-CI groups, respectively (P ¼ 0.07) (Figure 3b ). In multivariate analysis within patients with low-risk diseases, intermediate-and high-risk HCT-CI significantly predicted worse OS. High-risk HCT-CI was an independent predictor of NRM, and there was a trend towards increased NRM in patients with intermediate-risk HCT-CI (Table 3) .
For patients with high-risk diseases, 3-year OS was 43.6, 47.8 and 25.8% in the low-, intermediate-and high-risk HCT-CI groups, respectively (P ¼ 0.04) (Figure 3c ). Threeyear cumulative NRM was 16.4, 21.7 and 29.0% in the low-, intermediate-and high-risk HCT-CI groups, respectively (P ¼ 0.29) (Figure 3d ). In multivariate analysis within patients with high-risk diseases, intermediate-and high-risk HCT-CI did not predict OS or NRM (Table 3) .
Causes of death within 1 year after transplantation
A total of 55 patients died within 1 year post transplant, 30 from nonrelapse causes and 25 from relapses. Causes of NRM among these 30 patients included infections (n ¼ 12), GVHD (n ¼ 9), organ failure or toxicities (n ¼ 8) and other causes (n ¼ 1). Although there was no difference in the mortality from infections and GVHD among the three 
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HCT-CI score 0 HCT-CI score 1-2 HCT-CI score ≥3 Impact of HCT-CI by disease risk and time from SCT K Kataoka et al HCT-CI groups, patients with higher HCT-CI were more likely to die from organ failure or toxicities (0, 3 and 11% in the low-, intermediate-and high-risk HCT-CI groups, respectively; Po0.01).
Impact of HCT-CI on late mortality
To clarify the impact of the HCT-CI on late (X1 year) NRM after allogeneic HSCT, we investigated whether the HCT-CI predicts NRM in patients who survived without relapse 41 year after HSCT and compared its influence on late NRM with that of extensive chronic GVHD, a known risk factor for late NRM. 9, 10 One hundred and thirteen (60%) patients survived without relapse 41 year after HSCT. Within this cohort, 3-year OS was 94.6, 85.9 and 95.2% in the low-, intermediate-and high-risk HCT-CI groups, respectively (P ¼ 0.59). Three-year cumulative NRM was 2.7, 7.1 and 4.8% in the low-, intermediateand high-risk HCT-CI groups, respectively (P ¼ 0.31). In subgroup analysis within this cohort, OS and NRM did not differ significantly among the three HCT-CI groups.
Overall, the cumulative incidence of extensive chronic GVHD was 42.8%. Within patients who survived without relapse 41 year after HSCT, 44 patients with extensive chronic GVHD at 1 year had worse 3-year OS (85.3% vs 95.6%; Po0.01) and NRM (9.8% vs 1.4%; Po0.01) than 69 patients without extensive chronic GVHD. Thus, the HCT-CI would not be a better predictor of late OS and NRM than extensive chronic GVHD.
Discussion
Pretransplant assessment of comorbidities is an important aspect of risk-adapted decision making for HSCT candidates. The HCT-CI combines pretransplant comorbidities with varying impacts on transplant-related morbidity and mortality into a single score and is the first step towards incorporating comorbidities in clinical decision analysis for HSCT and risk adjustment for clinical trials. 1 The current analysis extended earlier reports on the role of the HCT-CI Table 2 Factors associated with overall survival and nonrelapse mortality within whole cohort: multivariate analysis Abbreviations: CI ¼ confidence interval; HCT-CI ¼ haematopoietic cell transplantation-specific comorbidity index; RR ¼ relative risk. a Cox proportional-hazards regression model was used for overall survival, and Fine and Gray's proportional-hazards model for subdistribution of a competing risk was used for cumulative nonrelapse mortality.
in allogeneic HSCT. In this study, we showed that the HCT-CI was associated with a decreased OS and an elevated NRM in patients receiving allogeneic HSCT for unselected haematologic malignancies at a single Japanese transplant centre. In addition, the HCT-CI was a good indicator of OS and NRM in patients with low-risk diseases, but did not predict transplant outcomes in those with high-risk diseases. Moreover, the HCT-CI was not associated with OS or NRM in patients who survived without relapse 41 year after HSCT.
Although the HCT-CI was recently evaluated as a predictor of transplant outcomes across various disease types, [2] [3] [4] 6, [14] [15] [16] conditioning regimens 5, 6, 15 and donor sources, 17 the versatility of this tool in various populations with different comorbidity composition remains to be verified. In this study, we showed that high-risk HCT-CI score was associated with a decreased OS and an elevated NRM, but intermediate-risk HCT-CI did not significantly predict OS or NRM. Our findings indicate that, in Japanese population, the HCT-CI could be an important predictor The limited influence of the HCT-CI in our patient population could be attributed to specific characteristics of our Japanese cohort. The prevalence of comorbidities was different in our population. Earlier studies on the HCT-CI performed in western countries reported that common pretransplant comorbidities were pulmonary (33-66%), hepatic (6-53%), psychiatric (5-20%), cardiac (5-16%), prior solid tumour (2-19%), infections (4-30%) and obesity (2-16%). 1, 3, 6, 15, 17, 18 The current study population had comparable proportions of patients with hepatic (42%), pulmonary (35%) and infectious (6%) diseases. However, a smaller proportion in this Japanese cohort had obesity (0%), psychiatric disturbance (3%) and cardiac disease (4%) than those in western countries. These results are consistent with the differences in the actual incidence and prevalence of these comorbidities in the general population between them. 19, 20 Comorbidities involving different organ systems could have a different impact on the risk of NRM after HSCT. Another reason for the lower discriminatory ability of the HCT-CI might be the different incidence of a major post-HSCT complication. Prior studies showed that Japanese patients have a lower incidence of acute GVHD than do white patients after the receipt of cells from either HLA-matched siblings or unrelated donors, 21, 22 which could be associated with a lower risk of NRM. This limited impact of the HCT-CI on transplant outcomes in our Japanese cohort might bring out a need for international multicentre studies before the HCT-CI is used for clinical decision making and comparison of trial results from different institutions.
In the subgroup analysis according to disease status, the HCT-CI was significantly associated with OS and NRM in patients with low-risk diseases, but did not predict OS or NRM in those with high-risk diseases. These findings are consistent with earlier reports from the Fred Hutchinson Cancer Research Centre. The HCT-CI was associated with pronounced-hazard ratios for OS (3.31 in intermediate-risk and 7.45 in high-risk HCT-CI groups, respectively) and NRM (3.43 and 8.12) in patients with acute myeloid leukaemia in first remission, 3 whereas this score was associated with moderate-hazard ratios for OS (1.76 and 3.13) and NRM (1.69 and 3.69) in those with unselected acute myeloid leukaemia or myelodysplastic syndrome. 2 These findings suggest that it is important to incorporate the HCT-CI into the risk-adapted decision making for HSCT candidates with low-risk diseases, but further study is needed on the use of this tool in patients with high-risk diseases.
In subgroup analysis within patients who survived without relapse 41 year after HSCT, the HCT-CI did not predict significant OS or NRM. These results indicate that pretransplant comorbidities did not affect late mortality after allogeneic HSCT. To improve the transplant outcomes in patients with coexisting comorbidities, it is important to focus on reducing early NRM after allogeneic HSCT.
This study has the typical limitation of a retrospective cohort study. Although clinical and laboratory information needed to calculate the HCT-CI was abstracted from medical charts, most of these data are routinely collected during pretransplant workup at our institution. In the subgroup analysis of patients with high-risk diseases, the sample size was relatively small and a considerable proportion of patients experienced relapse, which could be responsible for the weaker discriminatory ability of the HCT-CI in this analysis. Similarly, the small number of patients surviving 41 year limits the subgroup analysis of the impact of HCT-CI on late mortality. In addition, although the findings of subgroup analyses were consistent with theoretical explanation and the results of earlier studies, inherent multiplicity bias of these analyses might exist.
In conclusion, we showed that the HCT-CI could predict OS and NRM in Japanese HSCT recipients with unselected haematologic malignancies. In addition, the HCT-CI was a good prognostic indicator in patients with low-risk diseases, but not in those with high-risk diseases. Moreover, the HCT-CI was not associated with late OS or NRM. These results emphasize that the HCT-CI is a novel and simple tool that integrates pretransplant comorbidities into one index that predicts NRM and OS. However, the HCT-CI had differential prognostic impacts according to disease status and time from transplant. These findings can be useful to determine the role of comorbidity information in the risk-adapted decision making for HSCT candidates, comparison of trial results from different institutions and design of new clinical trials.
